Oestrogel (Estradiol)

Estradiol, the active ingredient in Oestrogel, is a estrogen presented as a transdermal gel for skin application. It treats estrogen deficiency and relieves menopausal symptoms in women. GNH USA supplies Oestrogel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oestrogel, an estrogen therapy, is used to address conditions related to low endogenous estrogen. - Menopausal symptom relief: reduces hot flashes, night sweats, and vaginal dryness. - Estrogen deficiency: restores physiologic estrogen levels in hypo‑estrogenic states. - Bone health support: contributes to maintenance of bone mineral density in post‑menopausal women.

Common Side Effects: - Skin irritation at the application site: redness, itching, or rash. - Nausea: mild to moderate upset stomach. - Headache: transient tension‑type headaches. - Breast tenderness: mild swelling or discomfort. - Mood changes: irritability or mild depressive symptoms. - Fluid retention: mild peripheral edema.

Serious or Rare Side Effects: - Deep vein thrombosis: swelling, pain, or redness in a limb. - Pulmonary embolism: sudden shortness of breath, chest pain. - Stroke: sudden neurological deficits. - Myocardial infarction: chest discomfort, radiating pain. - Endometrial hyperplasia: abnormal uterine bleeding. - Liver dysfunction: jaundice, elevated liver enzymes.

Before initiating Oestrogel, consider the following precautions. - Cardiovascular risk assessment: evaluate history of thromboembolic events. - Cancer screening: ensure no active breast or endometrial cancer. - Pregnancy avoidance: contraindicated in pregnancy; use effective contraception. - Breastfeeding: avoid use while nursing due to potential infant exposure. - Lowest effective dose: prescribe the minimal dose needed for symptom control. - Store at room temperature: keep in the original container, protect from light and moisture.

Oestrogel may interact with several medicines; monitoring is advised. Major Interactions (Avoid): - Combined oral contraceptives: increased estrogen load may raise thrombotic risk. - Anticoagulants (e.g., warfarin): altered clotting parameters. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise estradiol plasma levels. Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood pressure control. - Thyroid hormone replacement: may require dose adjustment. - Selective serotonin reuptake inhibitors: can affect hot‑flash management.